Comparison of changes in lipid profiles of premenopausal women with early-stage breast cancer treated with different endocrine therapies

  • Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71, 209–249. https://doi.org/10.3322/caac.21660 (2021).

    Article 

    Google Scholar
     

  • Liu, T., Song, S., Wang, X. & Hao, J. Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer. Eur. J. Med. Chem. 210, 112954. https://doi.org/10.1016/j.ejmech.2020.112954 (2021).

    Article 

    Google Scholar
     

  • Roberto, M. et al. CDK4/6 inhibitor treatments in patients with hormone receptor positive, Her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives. Cancers (Basel) https://doi.org/10.3390/cancers13020332 (2021).

    Article 

    Google Scholar
     

  • Collin, L. J. et al. Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-3974 (2020).

    Article 
    ADS 

    Google Scholar
     

  • Ouyang, P., Michos, E. D. & Karas, R. H. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J. Am. Coll. Cardiol. 47, 1741–1753. https://doi.org/10.1016/j.jacc.2005.10.076 (2006).

    Article 

    Google Scholar
     

  • Akyol, M. et al. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy. Cancer Biomark 18, 441–449. https://doi.org/10.3233/CBM-161507 (2017).

    Article 

    Google Scholar
     

  • He, T. et al. Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis. Med. (Baltim.) 99, e18550. https://doi.org/10.1097/MD.0000000000018550 (2020).

    Article 

    Google Scholar
     

  • Afifi, A. M. et al. Causes of death after breast cancer diagnosis: A US population-based analysis. Cancer 126, 1559–1567. https://doi.org/10.1002/cncr.32648 (2019).

    Article 

    Google Scholar
     

  • Anagnostis, P. et al. Menopause symptom management in women with dyslipidemias: An EMAS clinical guide. Maturitas 135, 82–88. https://doi.org/10.1016/j.maturitas.2020.03.007 (2020).

    Article 

    Google Scholar
     

  • Franchi, M., Tritto, R., Tarantini, L., Navazio, A. & Corrao, G. Adjuvant hormonotherapy and cardiovascular risk in post-menopausal women with breast cancer: A large population-based cohort study. Cancers (Basel) https://doi.org/10.3390/cancers13092254 (2021).

    Article 

    Google Scholar
     

  • Borgquist, S. et al. Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1–98 study. J. Clin. Oncol. 35, 1179–1188. https://doi.org/10.1200/JCO.2016.70.3116 (2017).

    Article 

    Google Scholar
     

  • Nelson, E. R. The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer. Mol. Cell Endocrinol. 466, 73–80. https://doi.org/10.1016/j.mce.2017.09.021 (2018).

    Article 

    Google Scholar
     

  • Lintermans, A. & Neven, P. Safety of aromatase inhibitor therapy in breast cancer. Expert Opin. Drug Saf. 14, 1201–1211. https://doi.org/10.1517/14740338.2015.1053458 (2015).

    Article 

    Google Scholar
     

  • Li, X. et al. Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. Lipids Health Dis. 17, 91. https://doi.org/10.1186/s12944-018-0745-1 (2018).

    Article 

    Google Scholar
     

  • Montemurro, F., Perrone, F. & Geuna, E. Adjuvant ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 372, 1672–1673. https://doi.org/10.1056/NEJMc1502618 (2015).

    Article 

    Google Scholar
     

  • Gaibar, M. et al. Tamoxifen therapy in breast cancer: Do apolipoprotein E genotype and menopausal state affect plasma lipid changes induced by the drug?. Int. J. Biol. Mark. 28, e371-376. https://doi.org/10.5301/jbm.5000037 (2013).

    Article 

    Google Scholar
     

  • Dnistrian, A. M., Schwartz, M. K., Greenberg, E. J., Smith, C. A. & Schwartz, D. C. Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy. Clin. Chim. Acta 223, 43–52. https://doi.org/10.1016/0009-8981(93)90061-8 (1993).

    Article 

    Google Scholar
     

  • Yang, H. et al. Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: A randomised controlled clinical trial. Br. J. Cancer 109, 582–588. https://doi.org/10.1038/bjc.2013.324 (2013).

    Article 

    Google Scholar
     

  • Bellet, M. et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy. J. Clin. Oncol. 34, 1584–1593. https://doi.org/10.1200/JCO.2015.61.2259 (2016).

    Article 

    Google Scholar
     

  • Ramchand, S. K., Lim, E. & Grossmann, M. Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: How should the skeletal and vascular side effects be assessed and managed?. Clin. Endocrinol. (Oxf.) 85, 689–693. https://doi.org/10.1111/cen.13172 (2016).

    Article 

    Google Scholar
     

  • Boccardo, F. et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann. Oncol. 17(Suppl 7), vii10-14. https://doi.org/10.1093/annonc/mdl941 (2006).

    Article 

    Google Scholar
     

  • Williams, N. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9, 45–53 (2008).

    Article 

    Google Scholar
     

  • Goss, P. E. et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793–1802. https://doi.org/10.1056/NEJMoa032312 (2003).

    Article 

    Google Scholar
     

  • Kawase, T. et al. Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan. Cancer Sci. 101, 1234–1240. https://doi.org/10.1111/j.1349-7006.2010.01496.x (2010).

    Article 

    Google Scholar
     

  • Pagani, O. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 371, 107–118. https://doi.org/10.1056/NEJMoa1404037 (2014).

    Article 

    Google Scholar
     

  • Tian, W., Wu, M. & Deng, Y. Comparison of changes in the lipid profiles of eastern chinese postmenopausal women with early-stage breast cancer treated with different aromatase inhibitors: A retrospective study. Clin. Pharmacol. Drug Dev. 7, 837–843. https://doi.org/10.1002/cpdd.420 (2018).

    Article 

    Google Scholar
     

  • Zhao, X. et al. Comparative study on individual aromatase inhibitors on cardiovascular safety profile: A network meta-analysis. Oncol. Targets Ther. 8, 2721–2730. https://doi.org/10.2147/OTT.S88179 (2015).

    Article 

    Google Scholar
     

  • Ntukidem, N. I. et al. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin. Pharmacol. Ther. 83, 702–710. https://doi.org/10.1038/sj.clpt.6100343 (2008).

    Article 

    Google Scholar
     

  • McCloskey, E. V. et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur. J. Cancer 43, 2523–2531. https://doi.org/10.1016/j.ejca.2007.08.029 (2007).

    Article 

    Google Scholar
     

  • Smith, I. et al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: Final results of the randomized phase III femara versus anastrozole clinical evaluation (FACE) trial. J. Clin. Oncol. 35, 1041–1048. https://doi.org/10.1200/JCO.2016.69.2871 (2017).

    Article 

    Google Scholar
     

  • Wang, X. et al. Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: A prospective cohort study. Ther. Adv. Med. Oncol. 12, 1758835920925991. https://doi.org/10.1177/1758835920925991 (2020).

    Article 

    Google Scholar
     

  • Santa-Maria, C. A. et al. Association of variants in candidate genes with lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy. Clin. Cancer Res. 22, 1395–1402. https://doi.org/10.1158/1078-0432.CCR-15-1213 (2016).

    Article 

    Google Scholar
     

  • Yeo, W. et al. Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy. BMC Womens Health 17, 55. https://doi.org/10.1186/s12905-017-0409-8 (2017).

    Article 

    Google Scholar